News

At 2009 GlobalChem Conference, Susan Sharkey of EPA told the attendees to expect changes to the next Inventory Update Rule (IUR). She also stated that 2006 IUR contained

Specifically, this approval is for post-exposure prophylaxis use of HepaGam B, ie for treatment of acute exposure to blood containing hepatitis B surface antigen (HBsAg), perinatal exposure of

The allergen challenge trial is a double-blind, placebo-controlled, parallel group study that is designed to assess the safety and efficacy of senicapoc administered orally on pulmonary function in

Dr Brawer will assist GTx chief medical officer Ronald Morton, Jr, and vice president of medical affairs Shontelle Dodson in educating the medical community about disease states of

Acorda received a refuse to file (RTF) letter for the Fampridine-SR new drug application (NDA) on March 30, 2009, which cited the need to correct ‘format issues’ and

Prior to joining Biocodex Inc, Mr Rohman was part of the senior management team at FlowMedica in Fremont, California, where he was responsible for directing the company’s collaboration

The company has reported net income available to common shareholders of $767 million for the first quarter of 2009 compared to $276 million for the same quarter of

For the first quarter of 2009, total sales were $5.38 billion, a decrease of 8%, compared to $5.82 billion in the same quarter of 2008. Richard Clark, chairman,

Net income attributable to Gilead was $589.11 million or $0.63 diluted earnings per share, for the first quarter of 2009, compared to $488.30 million, or $0.51 diluted earnings